 The design of the study will be randomized, double blind trial, which will examine the effects of Rosiglitazone on the fasting triglycerides TG, high-density lipoprotein HDL, low-density lipoprotein LDL, and plasma concentrations of apolipoproteins A-I, A-II, and C-III as compared to Fenofibrate and placebo. This study will also assess the synergistic effect of Rosiglitazone and Fenofibrate on the same parameters. Data from this study will help clarify whether Rosiglitazone favorably impacts plasma lipid and lipoprotein concentrations through improving insulin sensitivity and glycemic control, or by directly influencing the synthesis of the apolipoproteins that are responsible for very-low-density lipoprotein VLDL and HDL metabolism. 